Bluebird Bio to Be Taken Private by Carlyle and SK Capital Amid Cash Crunch
(Reuters) - Gene therapy maker Bluebird bio said on Friday it would be taken private by Carlyle and SK Capital Partners, ...
Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker
Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.
Citibank Joins Private Sector Retreat From Diversity Initiatives
In a politically charged business climate, the global banking giant joins peers in ending many diversity, equity, and ...
PE Hub18h
Carlyle and SK Capital to take gene therapy firm bluebird bio private
The Carlyle Group and SK Capital Partners have agreed to acquire bluebird bio, Inc, a Somerville, Massachusetts-based gene therapy firm, in a take-private deal. According to terms of the agreement, ...
GlobalData on MSN15h
Struggling bluebird bio to go private for less than $30m
Bluebird bio will be acquired by investment firms Carlyle and SK Capital Partners, marking the end to its turbulent time as a ...
Private Credit Mints a New Billionaire Class
Hi, it’s Tom Maloney in New York and Benjamin Stupples in London, looking at the wealth of Wall Street’s latest rock stars.